As of 2025-12-24, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (2.60) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.12 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -114.3%.
The range of the Relative Valuation is (1.85) - (3.54) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 14.8x | 10.0x |
| Forward P/E multiples | 7.7x - 15.7x | 11.7x |
| Fair Price | (1.85) - (3.54) | (2.60) |
| Upside | -110.2% - -119.5% | -114.3% |
| Date | P/E |
| 2025-12-23 | -74.89 |
| 2025-12-22 | -75.98 |
| 2025-12-19 | -74.59 |
| 2025-12-18 | -71.33 |
| 2025-12-17 | -71.20 |
| 2025-12-16 | -72.12 |
| 2025-12-15 | -72.75 |
| 2025-12-12 | -73.55 |
| 2025-12-11 | -75.31 |
| 2025-12-10 | -75.10 |
| 2025-12-09 | -71.25 |
| 2025-12-08 | -77.96 |
| 2025-12-05 | -76.64 |
| 2025-12-04 | -78.74 |
| 2025-12-03 | -76.90 |
| 2025-12-02 | -72.21 |
| 2025-12-01 | -72.25 |
| 2025-11-28 | -74.89 |
| 2025-11-26 | -74.59 |
| 2025-11-25 | -73.84 |
| 2025-11-24 | -74.68 |
| 2025-11-21 | -67.77 |
| 2025-11-20 | -68.86 |
| 2025-11-19 | -69.32 |
| 2025-11-18 | -70.37 |
| 2025-11-17 | -70.95 |
| 2025-11-14 | -75.47 |
| 2025-11-13 | -76.44 |
| 2025-11-12 | -78.82 |
| 2025-11-11 | -80.20 |
| 2025-11-10 | -76.60 |
| 2025-11-07 | -76.10 |
| 2025-11-06 | -77.23 |
| 2025-11-05 | -75.64 |
| 2025-11-04 | -73.21 |
| 2025-11-03 | -76.27 |
| 2025-10-31 | -79.16 |
| 2025-10-30 | -78.03 |
| 2025-10-29 | -78.11 |
| 2025-10-28 | -80.50 |
| 2025-10-27 | -81.46 |
| 2025-10-24 | -80.71 |
| 2025-10-23 | -78.49 |
| 2025-10-22 | -80.20 |
| 2025-10-21 | -78.44 |
| 2025-10-20 | -83.87 |
| 2025-10-17 | -87.86 |
| 2025-10-16 | -91.97 |
| 2025-10-15 | -94.77 |
| 2025-10-14 | -91.04 |